Human T cell lymphotropic virus type 1 (HTLV‐1) proviral load of HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP
- 12 May 2011
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (7), 1269-1274
- https://doi.org/10.1002/jmv.22087
Abstract
A high human T‐cell lymphotropic virus type 1 (HTLV‐1) proviral load is described in HTLV‐1‐associated diseases, especially HAM/TSP. However, the cut‐off value to define high levels of HTLV‐1 proviral load is not well established. 281 HTLV‐1‐infected patients from the HTLV reference center in Salvador, Brazil, were followed from 2005 to 2008. Patients were classified as asymptomatic, possible‐, probable‐, and definite‐HAM/TSP, in accordance with diagnostic criteria proposed by De Castro‐Costa et al. (2006): AIDS Res Hum Retroviruses 22:931–935. HTLV‐1 proviral load was determined using real‐time PCR. A receiver operator characteristic (ROC) curve was constructed using only asymptomatic individuals and definite‐HAM/TSP patients. The ROC curve was used to predict the proviral load level that differentiates these two groups. Out of 281 patients, 189 were asymptomatic and 92 were diagnosed with HAM/TSP (22 possible, 23 probable, 47 definite). The mean HTLV‐1 proviral load was higher in possible‐ (89,104 ± 93,006 copies/106 PBMC), ‐probable (175,854 ± 128,083 copies/106 PBMC), and definite‐HAM/TSP patients (150,667 ± 122,320 copies/106 PBMC), when compared to asymptomatic individuals (27,178 ± 41,155 copies/106 PBMC) (P < 0.0001). A comparison of all HAM/TSP groups showed the highest proviral loads in probable‐HAM/TSP patients, yet the differences in mean values were not statistically significant. The ROC curve suggested a value of 49,865 copies/106 PBMC, with 87% sensitivity (95% CI = 74–95) and 81% specificity (95% CI = 75–86), as the best proviral load cut‐off point to differentiate definite HAM/TSP patients from asymptomatic individuals. HTLV‐1 proviral loads are higher in groups of infected patients with neurological symptoms and may represent a relevant biological marker of disease progression. J. Med. Virol. 83:1269–1274, 2011.Keywords
This publication has 33 references indexed in Scilit:
- Quantifying HTLV‐I dynamicsImmunology & Cell Biology, 2007
- Human T Lymphotropic Virus Type 1 (HTLV-1) Proviral Load in Asymptomatic Carriers, HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis, and Other Neurological Abnormalities Associated with HTLV-1 InfectionClinical Infectious Diseases, 2007
- Long‐Term Variations in Human T Lymphotropic Virus (HTLV)–I and HTLV‐II Proviral Loads and Association with Clinical DataThe Journal of Infectious Diseases, 2006
- Proposal for Diagnostic Criteria of Tropical Spastic Paraparesis/HTLV-I-Associated Myelopathy (TSP/HAM)AIDS Research and Human Retroviruses, 2006
- Global epidemiology of HTLV-I infection and associated diseasesOncogene, 2005
- Role of HTLV‐1 proviral DNA load and clonality in the development of adult T‐cell leukemia/lymphoma in asymptomatic carriersInternational Journal of Cancer, 2004
- An HTLV-I Vaccine: Why, How, for Whom?AIDS Research and Human Retroviruses, 1993
- HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITYThe Lancet, 1986
- ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESISThe Lancet, 1985
- HIGH INCIDENCE OF HTLV ANTIBODY IN CARRIERS OF STRONGYLOIDES STERCORALISThe Lancet, 1984